Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.04
TMO's Cash-to-Debt is ranked lower than
96% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. TMO: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
TMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.39 Max: N/A
Current: 0.04
Equity-to-Asset 0.48
TMO's Equity-to-Asset is ranked lower than
72% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TMO: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
TMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.75
Current: 0.48
0.31
0.75
Interest Coverage 5.19
TMO's Interest Coverage is ranked lower than
77% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. TMO: 5.19 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 5.22  Med: 6.56 Max: 14.24
Current: 5.19
5.22
14.24
Piotroski F-Score: 8
Altman Z-Score: 2.84
Beneish M-Score: -2.42
WACC vs ROIC
7.33%
7.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 13.89
TMO's Operating Margin % is ranked higher than
77% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. TMO: 13.89 )
Ranked among companies with meaningful Operating Margin % only.
TMO' s Operating Margin % Range Over the Past 10 Years
Min: 10  Med: 11.78 Max: 14.82
Current: 13.89
10
14.82
Net Margin % 11.80
TMO's Net Margin % is ranked higher than
83% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. TMO: 11.80 )
Ranked among companies with meaningful Net Margin % only.
TMO' s Net Margin % Range Over the Past 10 Years
Min: 7.81  Med: 9.77 Max: 11.64
Current: 11.8
7.81
11.64
ROE % 10.43
TMO's ROE % is ranked higher than
67% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. TMO: 10.43 )
Ranked among companies with meaningful ROE % only.
TMO' s ROE % Range Over the Past 10 Years
Min: 5.36  Med: 7.8 Max: 10.13
Current: 10.43
5.36
10.13
ROA % 4.95
TMO's ROA % is ranked higher than
68% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. TMO: 4.95 )
Ranked among companies with meaningful ROA % only.
TMO' s ROA % Range Over the Past 10 Years
Min: 3.58  Med: 4.65 Max: 5.52
Current: 4.95
3.58
5.52
ROC (Joel Greenblatt) % 49.60
TMO's ROC (Joel Greenblatt) % is ranked higher than
79% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. TMO: 49.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 37.47  Med: 42.04 Max: 62.88
Current: 49.6
37.47
62.88
3-Year Revenue Growth Rate 8.70
TMO's 3-Year Revenue Growth Rate is ranked higher than
58% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. TMO: 8.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 7.3 Max: 18.7
Current: 8.7
-12.9
18.7
3-Year EBITDA Growth Rate 14.90
TMO's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TMO: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 14.9 Max: 40.9
Current: 14.9
-30.1
40.9
3-Year EPS without NRI Growth Rate 13.40
TMO's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. TMO: 13.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: 14 Max: 74.6
Current: 13.4
-43.5
74.6
GuruFocus has detected 6 Warning Signs with Thermo Fisher Scientific Inc $TMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TMO's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TMO Guru Trades in Q3 2016

Ken Fisher 1,482 sh (New)
Pioneer Investments 2,645,237 sh (+1.98%)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (+64.08%)
First Eagle Investment 200 sh (unchged)
Joel Greenblatt Sold Out
John Rogers 526,143 sh (-1.94%)
PRIMECAP Management 5,204,870 sh (-2.94%)
Diamond Hill Capital 551,677 sh (-3.90%)
David Dreman 9,343 sh (-4.77%)
Vanguard Health Care Fund 4,097,300 sh (-5.06%)
Mairs and Power 1,683 sh (-5.77%)
Larry Robbins 2,686,316 sh (-6.02%)
First Pacific Advisors 1,676,150 sh (-6.30%)
Steven Romick 1,306,510 sh (-7.72%)
Ray Dalio 10,600 sh (-14.97%)
Mario Gabelli 27,345 sh (-15.98%)
Signature Select Canadian Fund 72,350 sh (-16.07%)
Paul Tudor Jones 3,000 sh (-16.67%)
Manning & Napier Advisors, Inc 413,541 sh (-34.50%)
Dodge & Cox 67,602 sh (-87.16%)
» More
Q4 2016

TMO Guru Trades in Q4 2016

Wallace Weitz 132,160 sh (New)
Steven Cohen 183,552 sh (New)
Jim Simons 813,644 sh (New)
Caxton Associates 40,000 sh (New)
Ray Dalio 28,700 sh (+170.75%)
Larry Robbins 3,659,734 sh (+36.24%)
Diamond Hill Capital 647,502 sh (+17.37%)
Ken Fisher 1,707 sh (+15.18%)
Mario Gabelli 29,220 sh (+6.86%)
PRIMECAP Management 5,304,730 sh (+1.92%)
Manning & Napier Advisors, Inc 415,211 sh (+0.40%)
First Eagle Investment 200 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (unchged)
David Dreman 8,862 sh (-5.15%)
Vanguard Health Care Fund 3,884,800 sh (-5.19%)
John Rogers 483,526 sh (-8.10%)
First Pacific Advisors 1,460,100 sh (-12.89%)
Steven Romick 1,134,900 sh (-13.13%)
Paul Tudor Jones 2,500 sh (-16.67%)
Pioneer Investments 2,185,073 sh (-17.40%)
Dodge & Cox 50,002 sh (-26.03%)
» More
Q1 2017

TMO Guru Trades in Q1 2017

Joel Greenblatt 10,891 sh (New)
David Tepper 160,000 sh (New)
Prem Watsa 1,344 sh (New)
Jeremy Grantham 1,800 sh (New)
Paul Tudor Jones 8,545 sh (+241.80%)
Jim Simons 1,373,044 sh (+68.75%)
Ken Fisher 2,602 sh (+52.43%)
Wallace Weitz 135,545 sh (+2.56%)
Pioneer Investments 2,219,085 sh (+1.56%)
Diamond Hill Capital 648,596 sh (+0.17%)
First Eagle Investment 200 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Steven Romick 1,134,900 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (unchged)
Steven Cohen Sold Out
Caxton Associates Sold Out
PRIMECAP Management 5,271,490 sh (-0.63%)
First Pacific Advisors 1,441,070 sh (-1.30%)
Mario Gabelli 28,825 sh (-1.35%)
Dodge & Cox 48,287 sh (-3.43%)
John Rogers 463,398 sh (-4.16%)
Vanguard Health Care Fund 3,721,300 sh (-4.21%)
Larry Robbins 2,972,060 sh (-18.79%)
Manning & Napier Advisors, Inc 327,503 sh (-21.12%)
Signature Select Canadian Fund 44,850 sh (-38.01%)
Ray Dalio 8,844 sh (-69.18%)
David Dreman 37 sh (-99.58%)
» More
Q2 2017

TMO Guru Trades in Q2 2017

Robert Olstein 23,000 sh (New)
Caxton Associates 3,300 sh (New)
Steven Cohen 126,605 sh (New)
David Tepper 375,000 sh (+134.38%)
Mario Gabelli 42,965 sh (+49.05%)
Ray Dalio 10,194 sh (+15.26%)
Diamond Hill Capital 714,693 sh (+10.19%)
First Pacific Advisors 1,462,520 sh (+1.49%)
Pioneer Investments 2,242,466 sh (+1.05%)
PRIMECAP Management 5,283,370 sh (+0.23%)
Steven Romick 1,134,900 sh (unchged)
First Eagle Investment 200 sh (unchged)
Prem Watsa 1,344 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Jeremy Grantham Sold Out
David Dreman Sold Out
Dodge & Cox 47,687 sh (-1.24%)
Wallace Weitz 131,545 sh (-2.95%)
Vanguard Health Care Fund 3,535,100 sh (-5.00%)
Larry Robbins 2,759,965 sh (-7.14%)
John Rogers 386,046 sh (-16.69%)
Manning & Napier Advisors, Inc 271,710 sh (-17.04%)
Jim Simons 760,144 sh (-44.64%)
Ken Fisher 1,284 sh (-50.65%)
Paul Tudor Jones 3,742 sh (-56.21%)
Joel Greenblatt 2,478 sh (-77.25%)
Eaton Vance Worldwide Health Sciences Fund 194,159 sh (-16.08%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -5.00%0.06%$152.18 - $176.44 $ 172.573%3,535,100
John Rogers 2017-06-30 Reduce -16.69%0.14%$152.18 - $176.44 $ 172.573%386,046
David Tepper 2017-06-30 Add 134.38%0.56%$152.18 - $176.44 $ 172.573%375,000
Wallace Weitz 2017-06-30 Reduce -2.95%0.03%$152.18 - $176.44 $ 172.573%131,545
Dodge & Cox 2017-06-30 Reduce -1.24%$152.18 - $176.44 $ 172.573%47,687
Mario Gabelli 2017-06-30 Add 49.05%0.02%$152.18 - $176.44 $ 172.573%42,965
Robert Olstein 2017-06-30 New Buy0.51%$152.18 - $176.44 $ 172.573%23,000
Joel Greenblatt 2017-06-30 Reduce -77.25%0.02%$152.18 - $176.44 $ 172.573%2,478
Ken Fisher 2017-06-30 Reduce -50.65%$152.18 - $176.44 $ 172.573%1,284
David Dreman 2017-06-30 Sold Out $152.18 - $176.44 $ 172.573%0
Vanguard Health Care Fund 2017-03-31 Reduce -4.21%0.06%$140.98 - $161.05 $ 172.5713%3,721,300
John Rogers 2017-03-31 Reduce -4.16%0.03%$140.98 - $161.05 $ 172.5713%463,398
David Tepper 2017-03-31 New Buy0.4%$140.98 - $161.05 $ 172.5713%160,000
Wallace Weitz 2017-03-31 Add 2.56%0.02%$140.98 - $161.05 $ 172.5713%135,545
Dodge & Cox 2017-03-31 Reduce -3.43%$140.98 - $161.05 $ 172.5713%48,287
Mario Gabelli 2017-03-31 Reduce -1.35%$140.98 - $161.05 $ 172.5713%28,825
Joel Greenblatt 2017-03-31 New Buy0.02%$140.98 - $161.05 $ 172.5713%10,891
Ken Fisher 2017-03-31 Add 52.43%$140.98 - $161.05 $ 172.5713%2,602
Prem Watsa 2017-03-31 New Buy0.02%$140.98 - $161.05 $ 172.5713%1,344
David Dreman 2017-03-31 Reduce -99.58%0.7%$140.98 - $161.05 $ 172.5713%37
Vanguard Health Care Fund 2016-12-31 Reduce -5.19%0.07%$139.63 - $159.12 $ 172.5717%3,884,800
John Rogers 2016-12-31 Reduce -8.10%0.08%$139.63 - $159.12 $ 172.5717%483,526
Wallace Weitz 2016-12-31 New Buy0.76%$139.63 - $159.12 $ 172.5717%132,160
Dodge & Cox 2016-12-31 Reduce -26.03%$139.63 - $159.12 $ 172.5717%50,002
Mario Gabelli 2016-12-31 Add 6.86%$139.63 - $159.12 $ 172.5717%29,220
David Dreman 2016-12-31 Reduce -5.15%0.05%$139.63 - $159.12 $ 172.5717%8,862
Ken Fisher 2016-12-31 Add 15.18%$139.63 - $159.12 $ 172.5717%1,707
Vanguard Health Care Fund 2016-09-30 Reduce -5.06%0.07%$143.68 - $159.56 $ 172.5712%4,097,300
John Rogers 2016-09-30 Reduce -1.94%0.02%$143.68 - $159.56 $ 172.5712%526,143
Dodge & Cox 2016-09-30 Reduce -87.16%0.07%$143.68 - $159.56 $ 172.5712%67,602
Mario Gabelli 2016-09-30 Reduce -15.98%$143.68 - $159.56 $ 172.5712%27,345
David Dreman 2016-09-30 Reduce -4.77%0.04%$143.68 - $159.56 $ 172.5712%9,343
Ken Fisher 2016-09-30 New Buy$143.68 - $159.56 $ 172.5712%1,482
Joel Greenblatt 2016-09-30 Sold Out $143.68 - $159.56 $ 172.5712%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541380    SIC: 3826
Compare:NYSE:DHR, NYSE:Q, NYSE:A, NYSE:LH, NYSE:DGX, NAS:IDXX, NYSE:PKI, NYSE:BIO, NAS:DXCM, NAS:INCR, NYSE:CRL, NAS:PRAH, NAS:EXAS, NAS:PRXL, NAS:BRKR, NAS:VWR, NYSE:ALR, NAS:NEOG, NAS:MYGN, NAS:FMI » details
Traded in other countries:TMOS34.Brazil, TN8.Germany, TMO.Mexico, TFS.Switzerland,
Headquarter Location:USA
Thermo Fisher Scientific Inc is a healthcare company. It offers analytical instruments, laboratory equipment, software, services, consumables, reagents and chemicals.

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments: analytical technologies (about 20% of sales after the FEI acquisition); specialty diagnostic products (17%); life science solutions (28% including Affymetrix); and lab products and services (35%).

Guru Investment Theses on Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific - Jan 26, 2017

Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

John Rogers Comments on Thermo Fisher Scientific Inc. - Jan 20, 2017

Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

Thermo Fisher Scientific Prices Offering of Senior Notes
Thermo Fisher Scientific Prices Offering of Common Stock
Thermo Fisher Extends Cash Tender Offer for All Outstanding Shares of Patheon to Coordinate Offer Timing with Two Remaining Regulatory Approvals
Thermo Fisher Scientific Announces $1.5 Billion Offering of Common Stock
Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
Thermo Fisher Scientific Declares Quarterly Dividend
Tracking Portfolio Performance With Risk Analysis A deep look at key portfolio statistics measures
The “Five Criteria for Good Companies” model portfolio generated solid returns during the backtesting period from January 2006-2017, outperforming the Standard & Poor’s 500 exchange-traded fund benchmark in nine of the past 12 years. As of June 20, the portfolio generated a cumulative return of 261.72%, yielding an average excess return of about 5.72%. Read more...
Thermo Fisher Scientific Raises the Bar in Mass Spectrometry Innovation at ASMS 2017
Thermo Fisher Scientific to Acquire Patheon, a Leading Contract Development and Manufacturing Organization (CDMO)

Ratios

vs
industry
vs
history
PE Ratio 30.06
TMO's PE Ratio is ranked higher than
58% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. TMO: 30.06 )
Ranked among companies with meaningful PE Ratio only.
TMO' s PE Ratio Range Over the Past 10 Years
Min: 12.67  Med: 26.58 Max: 62.79
Current: 30.06
12.67
62.79
Forward PE Ratio 18.73
TMO's Forward PE Ratio is ranked higher than
86% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. TMO: 18.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.01
TMO's PE Ratio without NRI is ranked higher than
58% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. TMO: 30.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
TMO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.48  Med: 26.58 Max: 62.07
Current: 30.01
13.48
62.07
Price-to-Owner-Earnings 26.28
TMO's Price-to-Owner-Earnings is ranked higher than
62% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. TMO: 26.28 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TMO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.21  Med: 18.99 Max: 107.6
Current: 26.28
9.21
107.6
PB Ratio 3.02
TMO's PB Ratio is ranked higher than
61% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. TMO: 3.02 )
Ranked among companies with meaningful PB Ratio only.
TMO' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.6 Max: 3.18
Current: 3.02
0.83
3.18
PS Ratio 3.55
TMO's PS Ratio is ranked lower than
51% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. TMO: 3.55 )
Ranked among companies with meaningful PS Ratio only.
TMO' s PS Ratio Range Over the Past 10 Years
Min: 1.24  Med: 2.52 Max: 3.75
Current: 3.55
1.24
3.75
Price-to-Free-Cash-Flow 25.09
TMO's Price-to-Free-Cash-Flow is ranked higher than
50% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. TMO: 25.09 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TMO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.2  Med: 20.08 Max: 34.98
Current: 25.09
10.2
34.98
Price-to-Operating-Cash-Flow 21.90
TMO's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. TMO: 21.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TMO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.72  Med: 17.18 Max: 28.82
Current: 21.9
8.72
28.82
EV-to-EBIT 31.32
TMO's EV-to-EBIT is ranked lower than
63% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TMO: 31.32 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.8  Med: 24 Max: 86.3
Current: 31.32
10.8
86.3
EV-to-EBITDA 18.65
TMO's EV-to-EBITDA is ranked higher than
52% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. TMO: 18.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 14.6 Max: 44.9
Current: 18.65
6.6
44.9
PEG Ratio 2.05
TMO's PEG Ratio is ranked higher than
69% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. TMO: 2.05 )
Ranked among companies with meaningful PEG Ratio only.
TMO' s PEG Ratio Range Over the Past 10 Years
Min: 0.51  Med: 1.68 Max: 2.95
Current: 2.05
0.51
2.95
Shiller PE Ratio 45.51
TMO's Shiller PE Ratio is ranked higher than
52% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. TMO: 45.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
TMO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.78  Med: 41.68 Max: 63.12
Current: 45.51
20.78
63.12
Current Ratio 1.47
TMO's Current Ratio is ranked lower than
80% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. TMO: 1.47 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.42 Max: 3.83
Current: 1.47
0.9
3.83
Quick Ratio 0.99
TMO's Quick Ratio is ranked lower than
84% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TMO: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.81 Max: 3.4
Current: 0.99
0.61
3.4
Days Inventory 80.37
TMO's Days Inventory is ranked higher than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. TMO: 80.37 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 77.48
Current: 80.37
65.13
77.48
Days Sales Outstanding 61.94
TMO's Days Sales Outstanding is ranked higher than
51% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. TMO: 61.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 60.89
Current: 61.94
50.89
60.89
Days Payable 34.50
TMO's Days Payable is ranked lower than
68% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. TMO: 34.50 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.52 Max: 41.58
Current: 34.5
31.3
41.58

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.35
TMO's Dividend Yield % is ranked lower than
89% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. TMO: 0.35 )
Ranked among companies with meaningful Dividend Yield % only.
TMO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.86
Current: 0.35
0.22
0.86
Dividend Payout Ratio 0.10
TMO's Dividend Payout Ratio is ranked higher than
98% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. TMO: 0.10 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TMO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.13 Max: 0.17
Current: 0.1
0.12
0.17
Forward Dividend Yield % 0.35
TMO's Forward Dividend Yield % is ranked lower than
91% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. TMO: 0.35 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.35
TMO's 5-Year Yield-on-Cost % is ranked lower than
90% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. TMO: 0.35 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TMO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.86
Current: 0.35
0.22
0.86
3-Year Average Share Buyback Ratio -2.80
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. TMO: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.3  Med: -3.8 Max: 4.4
Current: -2.8
-37.3
4.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.48
TMO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. TMO: 1.48 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TMO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.56 Max: 43.11
Current: 1.48
0.59
43.11
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.31
TMO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. TMO: 1.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.41
TMO's Price-to-Median-PS-Value is ranked lower than
74% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. TMO: 1.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.74 Max: 1.42
Current: 1.41
0.23
1.42
Price-to-Peter-Lynch-Fair-Value 2.32
TMO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
53% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. TMO: 2.32 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TMO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.66 Max: 14.2
Current: 2.32
0.64
14.2
Earnings Yield (Greenblatt) % 3.19
TMO's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. TMO: 3.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 4.2 Max: 9.3
Current: 3.19
1.2
9.3
Forward Rate of Return (Yacktman) % 16.19
TMO's Forward Rate of Return (Yacktman) % is ranked higher than
78% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. TMO: 16.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TMO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 13.6  Med: 20.8 Max: 33.9
Current: 16.19
13.6
33.9

More Statistics

Revenue (TTM) (Mil) $19,199.10
EPS (TTM) $ 5.74
Beta1.00
Short Percentage of Float0.95%
52-Week Range $139.07 - 182.87
Shares Outstanding (Mil)400.21

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,813 21,592 21,633
EPS ($) 9.21 10.29 10.98
EPS without NRI ($) 9.21 10.29 10.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.60%
Dividends per Share ($) 0.60 0.60 0.60
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Thermo Fisher Scientific Prices Offering of Senior Notes Aug 10 2017 
Thermo Fisher Scientific Prices Offering of Common Stock Aug 08 2017 
Thermo Fisher Extends Cash Tender Offer for All Outstanding Shares of Patheon to Coordinate Offer Ti Aug 07 2017 
Thermo Fisher Scientific Announces $1.5 Billion Offering of Common Stock Aug 07 2017 
Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017 Jul 31 2017 
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes Jul 18 2017 
Thermo Fisher Scientific Declares Quarterly Dividend Jul 12 2017 
Tracking Portfolio Performance With Risk Analysis Jun 20 2017 
Thermo Fisher Scientific Raises the Bar in Mass Spectrometry Innovation at ASMS 2017 Jun 05 2017 
Thermo Fisher Scientific to Acquire Patheon, a Leading Contract Development and Manufacturing Organi May 15 2017 

More From Other Websites
Edited Transcript of TMO earnings conference call or presentation 26-Jul-17 12:30pm GMT Aug 12 2017
See what the IHS Markit Score report has to say about Thermo Fisher Scientific Inc. Aug 12 2017
Thermo Fisher Scientific Prices Offering of Senior Notes Aug 10 2017
Thermo Fisher Scientific (Finance I) B.V. -- Moody's assigns Baa2 to Thermo Fisher's bond offering Aug 10 2017
Cramer: Secondary Offerings Get Primary Attention Aug 09 2017
Thermo Fisher Scientific Prices Offering of Common Stock Aug 08 2017
Thermo Fisher Scientific, Inc. – Value Analysis (NYSE:TMO) : August 8, 2017 Aug 08 2017
Thermo Fisher Scientific Announces $1.5 Billion Offering of Common Stock Aug 07 2017
Thermo Fisher Extends Cash Tender Offer for All Outstanding Shares of Patheon to Coordinate Offer... Aug 07 2017
Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bullish Manner : TMO-US :... Aug 07 2017
Earnings Review and Free Research Report: Thermo Fisher’s Revenue Jumped 10%; EPS Climbed 20% Aug 03 2017
How Thermo Fisher Scientific’s Stock Has Performed Aug 01 2017
Why Thermo Fisher Scientific Raised Its 2017 Guidance Jul 31 2017
Key Highlights from Thermo Fisher Scientific’s 2Q17 Earnings Jul 31 2017
What Analysts Recommend for Thermo Fisher Scientific Jul 31 2017
Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017 Jul 31 2017
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint? Jul 31 2017
Zimmer (ZBH) Tops Q2 Earnings, Drops View on Dull Sales Jul 27 2017
Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up Jul 27 2017
Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bearish Manner : TMO-US :... Jul 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}